All News
How Online Searches Reveal Patient Needs
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.
Read Article
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk.
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract #0614
What is the impact of Lupus on my quality of life?
Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM)
- high dose GC, comorbidities, and not actively working associated with worse impact on QoL
- HCQ shows benefit
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0477 🌍 Global prevalence of RA-ILD
➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281
🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use.
⛔️Wide CI = heterogeneity main limitation
💡 Screening & lifestyle changes key for high-risk groups.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA.
Makes sense in a way since longer dse duration may play a role.
🔶️THM - screen SpA pts for IBD; ask for GI symptoms
@RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z
sheila RHEUMarampa ( View Tweet)
High PBO effect in PsA studies
Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12:
💡PBO rates significantly increased over time.
💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe
Adela Castro AdelaCastro222 ( View Tweet)
#0582🔬Challenges in Achieving PsA Disease Control
➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively
🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes.
🩺Unmet needs remain in PsA; tailored Rx needed
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW
Links:
Mike Putman EBRheum ( View Tweet)
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335)
Risk high among Class III, IV, V and eGFR > 30
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0501
💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA
➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers
🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised
💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD
Links:
Richard Conway RichardPAConway ( View Tweet)
#Frailty leads to poor outcomes and occurs earlier in RA patients. Different tools measure frailty as a phenotype vs. deficit accumulation.
Discover the role of frailty in ED from #LancetRheum Ageing Series by Drs. Sarah Lieber and @KWyshamMD !
#ACR24 @RheumNow ABST#1334 https://t.co/25XQBDQMCo
Jiha Lee JihaRheum ( View Tweet)
Location of research matters Ab#0772
Global recruiting patterns impact PBO in PsA
PBO results improve w time - 0.9%/year
More globalization of trials w time
Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response
@RheumNow #ACR24
Eric Dein ericdeinmd ( View Tweet)
#0322🔬 Myocarditis in Myositis(IIM)
📊 26% new IIM pt had myocarditis (ESC,Lake Louise)
💥 Anti-Ku most common MSA
💥Myocarditis a/w ⬆️heart failure, arrhythmia (43 v 6%;p=0.02)
🎯 Myocarditis🟰poor outcomes
🎯Cardiac MRI🟰earlier detection
#ACR24 @RheumNow @JuliePaikMD https://t.co/yz0f2ozFVL
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow https://t.co/hErZVfs08k
David Liew drdavidliew ( View Tweet)
❓What factors influence patient participation in rheumatology #ClinicalTrials?
📌 Come to poster 0366 to find out!
👨🏻⚕️ @KKouranloo & @chriswincup report results from a UK study, showing marked differences by ethnicity & RMD
@RheumNow Ab0366 #ACR24 https://t.co/kAqGJmNiPt
Mrinalini Dey DrMiniDey ( View Tweet)
CV risk after gout attack
1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance)
@RheumNow
#ACR24 year in review Pillinger https://t.co/a2zS8mIw3L
Links:
Eric Dein ericdeinmd ( View Tweet)
RA pearls from #ACR24 review course:
1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
2. Multimorbidity=Poor outcomes, High risk for mortality.
3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person!
Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse.
@RheumNow https://t.co/NiaUXzt4nT
Jiha Lee JihaRheum ( View Tweet)
